Author : Akanksha prajapati
Keyword : Granisetron, palonosetron, chemotherapy induced nausea vomiting
Subject : Pharmacy
Article Type : Original article (research)
Article QR Code
Article File : Full Text PDF
Abstract : Abstract Dolasetron is a second generation 5-HT3 receptor antagonist administration in as a single intravenous (IV) dose for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy and prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Granisetron is a selective 5-HT3 receptor antagonist. It has been on the market since 1996 in Japan and a number of other Asian countries as an antiemetic drug for cancer patients receiving chemotherapy. The aim of this study was- to compare the effectiveness of two 5-HT3 antagonists- Dolasetron and Granisetron, for the prophylaxis of Chemotherapy induced nausea and vomiting (CINV), in both acute (upto 24 hours) and delayed (upto 7 days) phases, when given for moderate to highly emetogenic anticancer drugs in single intravenous dose half an hour before starting chemotherapy. A prospective, randomized, double-blinded interventional study. A total of hundred patients were selected randomly and were randomized into two groups (A and B) of 50 patients each. Group A received Inj Dolasetron 0.25 mg IV + Inj Dexamethasone 8 mg IV and group B received Inj Granisetron 0.3 mg IV + Inj Dexamethasone 8 mg IV. Complete response was taken as patient having no episodes of nausea and vomiting as well as not requiring any rescue medication. Various secondary efficacy parameters were taken into consideration: proportion of patients exhibiting episodes of immediate nausea, immediate vomiting, delayed nausea, delayed vomiting; need for rescue medication; time to emetic episode and assessment of severity of nausea and vomiting. This study showed that Dolasetron and Granisetron are equally effective in preventing chemotherapy induced nausea and vomiting with both moderate and highly emetogenic chemotherapeutic agents.
Article by : Dr Akanksha
Article add date : 2022-12-02
How to cite : Akanksha prajapati. (2022-December-02). Evaluation of newer anti-emetic drugs in prophylaxis of chemotherapy induced nausea and vomiting in cancer patients. retrieved from https://www.openacessjournal.com/abstract/1143